Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

GlaxoSmithKline PLC Director's Dealing 2017

Mar 23, 2017

5262_rns_2017-03-23_a389260e-23ca-4310-92ae-4679a32293e0.html

Director's Dealing

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 3911A

GlaxoSmithKline PLC

23 March 2017

GlaxoSmithKline plc (the 'Company')

Transaction notification

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr K Slaoui

b)

Position/status

PCA of Dr M M Slaoui (Chairman, Global Vaccines)

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053

b)

Nature of the transaction

An increase of 4 ADSs following the notional allocation of ADSs on 22 March 2017, at a price of $42.28 per ADS, as a result of the revaluation of the cash element of the notional investment held within the GSK 401(K) plan.

c)

Price(s) and volume(s)

Price(s) Volume(s)
$42.28 4

d)

Aggregated information

Aggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2017-03-22

f)

Place of the transaction

n/a

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHQXLFLDXFEBBZ